Melissa Cohen, MD
Medical Oncology · Simi Valley, CANPI 1174763262
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.1%), other and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Novartis at 44.8% of the total. 2025 is the largest year on record at $2,375, more than ten times the $85 reported in 2019. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 109 payments — averaging $45.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Daiichi Sankyo Inc.$404
- Pfizer$206
- Merck$179
- Astellas Pharma US Inc$178
- Incyte Corporation$167
- plus $2K from 26 others
What the payments were for
- Food & beverage$2,28146%
- Education$55011%
- Other$2,11243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $2,213 |
| Daiichi Sankyo Inc. | 8 | $404 |
| Pfizer | 13 | $206 |
| Merck | 4 | $179 |
| Astellas Pharma US Inc | 3 | $178 |
| Incyte Corporation | 5 | $167 |
| Bayer | 2 | $140 |
| AVEO Pharmaceuticals, Inc. | 3 | $134 |
| Covidien LP | 1 | $104 |
| GSK | 1 | $101 |
| Tempus AI, Inc | 3 | $96 |
| AstraZeneca | 3 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| Seagen Inc. | 1 | $73 |
| Puma Biotechnology, Inc. | 4 | $71 |
| Genentech USA, Inc. | 2 | $70 |
| Johnson & Johnson(2 entities) | 3 | $66 |
| AbbVie | 2 | $60 |
| Lilly USA, LLC | 2 | $54 |
| Gilead(2 entities) | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Array Biopharma Inc | 2 | $51 |
| Genmab U.S., Inc. | 2 | $47 |
| Tesaro, Inc. | 3 | $46 |
| Foundation Medicine, Inc. | 2 | $46 |
| Eisai Inc. | 1 | $29 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $26 |
| EMD Serono, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DATROWAY$149
- Nubeqa$124
- superDimension$104
- JEMPERLI$101
How this compares
$4,942 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $257,238 |
| EliquisApixaban | 21 | $16,362 |
| Imatinib Mesylate | 17 | $1,375 |
| Tamoxifen Citrate | 30 | $1,283 |
| Letrozole | 37 | $1,262 |
| Ondansetron OdtOndansetron | 21 | $445 |
| Hydroxyurea | 15 | $431 |
| Dexamethasone | 28 | $416 |
| Anastrozole | 29 | $389 |
| Acyclovir | 19 | $355 |
| Gabapentin | 22 | $295 |
| Prochlorperazine Maleate | 19 | $141 |
| Levofloxacin | 14 | $136 |
| Lorazepam | 22 | $76 |
| Prednisone | 15 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $178 | $257,23818 claims |
| PfizerEliquis | $206 | $16,36221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 379 medical oncology providers in California.
Other medical oncology in Simi Valley
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.